Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lepor, N. E."'
Autor:
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., Kastelein, J. J., ODYSSEY LONG TERM Investigators, Lembo, Giuseppe
Publikováno v:
Robinson, J G, Farnier, M, Krempf, M, Bergeron, J, Luc, G, Averna, M, Stroes, E S, Langslet, G, Raal, F J, El Shahawy, M, Koren, M J, Lepor, N E, Lorenzato, C, Pordy, R, Chaudhari, U, Kastelein, J J P, ODYSSEY LONG TERM Investigators & Torp-Pedersen, C 2015, ' Efficacy and safety of alirocumab in reducing lipids and cardiovascular events ', The New England Journal of Medicine, vol. 372, no. 16, pp. 1489-1499 . https://doi.org/10.1056/NEJMoa1501031
New England journal of medicine, 372(16), 1489-1499. Massachussetts Medical Society
New England Journal of Medicine
New England Journal of Medicine, 2015, 372 (16), pp.1489-1499. ⟨10.1056/NEJMoa1501031⟩
New England Journal of Medicine, Massachusetts Medical Society, 2015, 372 (16), pp.1489-1499. ⟨10.1056/NEJMoa1501031⟩
New England journal of medicine, 372(16), 1489-1499. Massachussetts Medical Society
New England Journal of Medicine
New England Journal of Medicine, 2015, 372 (16), pp.1489-1499. ⟨10.1056/NEJMoa1501031⟩
New England Journal of Medicine, Massachusetts Medical Society, 2015, 372 (16), pp.1489-1499. ⟨10.1056/NEJMoa1501031⟩
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48df7487c03f82bdbce1a49c5d5d435f
https://doi.org/10.1056/nejmoa1501031
https://doi.org/10.1056/nejmoa1501031
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Clinical Cardiology; 1989, Vol. 12 Issue 8, p432-434, 3p
Autor:
Lepor NE (AUTHOR), Gross SB (AUTHOR), Daley WL (AUTHOR), Samuels BA (AUTHOR), Rizzo MJ (AUTHOR), Luko SP (AUTHOR), Hickey A (AUTHOR), Buchbinder NA (AUTHOR), Naqvi TZ (AUTHOR), Lepor, N E1 (AUTHOR), Gross, S B (AUTHOR), Daley, W L (AUTHOR), Samuels, B A (AUTHOR), Rizzo, M J (AUTHOR), Luko, S P (AUTHOR), Hickey, A (AUTHOR), Buchbinder, N A (AUTHOR), Naqvi, T Z (AUTHOR)
Publikováno v:
American Journal of Cardiology. 07/01/2000, Vol. 86 Issue 1, p107-110. 4p.
Autor:
Nagai, Tomoo, Huai Luo, Nagai, T1 (AUTHOR), Luo, H (AUTHOR), Atar, S (AUTHOR), Lepor, N E (AUTHOR), Fishbein, M C (AUTHOR), Siegel, R J (AUTHOR)
Publikováno v:
American Journal of Cardiology. 01/01/99, Vol. 83 Issue 1, p135-135. 4p. 2 Black and White Photographs, 2 Diagrams.
Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III.
Publikováno v:
Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2001 Summer; Vol. 2 (3), pp. 160-5.
Autor:
Stone GW; Lenox Hill Hospital, New York, NY, USA., Tumlin JA, Madyoon H, Lepor NE, McCullough PA, Mathur VS, Murray PT, O'Neill WW
Publikováno v:
Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2001; Vol. 2 Suppl 1, pp. S31-6.
Autor:
Lepor NE; Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Publikováno v:
Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2001; Vol. 2 Suppl 1, pp. S1-3.
Autor:
Lepor NE; Cedars-Sinai Medical Center, Los Angeles, California, USA.
Publikováno v:
Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2000 Summer; Vol. 1 (1), pp. 43-54.